Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 1, 2015, Pages 87-93

  Takasu, Toshiyuki ^a   Hayashizaki, Yuka ^a   Tahara, Atsuo ^a   Kurosaki, Eiji ^a   Takakura, Shoji ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Antidiabetic drugs; Blood glucose; Ipragliflozin; Sodium glucose transporter 2; Type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; IPRAGLIFLOZIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; SITAGLIPTIN; VOGLIBOSE; ANTIDIABETIC AGENT; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; ORAL DRUG ADMINISTRATION; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCOSIDES; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED ICR; MICE, TRANSGENIC; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; TREATMENT OUTCOME;

EID: 84919609106     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12317     Document Type: Article

References (31)

1. Pouwer F, Hermanns N. Insulin therapy and quality of life. A review. Diabet. Metab. Res. Rev. 2009; 25(Suppl. 1): S4-10.
2. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabet. Res. Clin. Prac. 1995; 28: 103-17.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
4. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-94.
5. Luna B, Feinglos M. Oral agents in the management of type 2 diabetes mellitus. Am. Fam. Physician 2001; 63: 1747-56.
6. Bennett WL, Balfe LM, Faysal JM. AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: A summary of the key findings. J. Manag. Care Pharm. 2012; 1(Suppl. A): s3-20.
7. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995; 18: 1510-18.
8. Nathan DM, Holman RR, Buse JB et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009; 32: 193-203.
9. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in Patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-12.
10. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-42.
11. Vallon V, Platt KA, Cunard R et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J. Am. Soc. Nephrol. 2011; 22: 104-12.
12. Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of Na+/glucose cotransporters in renal proximal tubule cells. Kidney Int. 2007; 72: s27-35.
13. Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-9.
14. Oku A, Ueta K, Arakawa K et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999; 48: 1794-800.
15. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-33.
16. Rosenstock J, Salsali A, Vico M, List JF, Wei L. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-8.
17. Rosenstock J, Usiskin K, Aggarwal N et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-8.
18. Wilding JPH, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: A dose-finding study. Diabetes Obes. Metab. 2013; 15: 403-9.
19. Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol. Ther. 2013; 139: 51-9.
20. Imamura M, Nakanishi K, Suzuki T et al. Discovery of ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg. Med. Chem. 2012; 20: 3263-79.
21. Tahara A, Kurosaki E, Yokono M et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J. Pharmacol. Sci. 2012; 120: 36-44.
22. Tahara A, Kurosaki E, Yokono M et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 2012; 385: 423-36.
23. Tahara A, Kurosaki E, Yokono M et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur. J. Pharmacol. 2013; 715: 246-55.
24. Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J. Physiol. 2009; 587: 27-32.
25. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56: 117-26.
26. Iwatsuka H, Shino A, Suzuoki Z. General survey of diabetic features of yellow KK mice. Endocrinol. Jpn. 1970; 17: 23-35.
27. Shinozaki K, Suzuki M, Ikebuchi M, Hirose J, Hara Y, Harano Y. Improvement of insulin sensitivity and dyslipidemia with a new α-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism 1996; 45: 731-7.
28. Miura T, Ishihara E, Ishida H, Seino Y, Tanigawa K. A genetic non-insulin dependent diabetic mice KK-Ay mice, is elevated alpha-glucosyldisaccharide digestive/absorptive capacity in small intestine. Biomed. Res. 1998; 19: 335-8.
29. Hofmann CA, Edwards CW III, Hillman RM, Colca JR. Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: Evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression. Endocrinol 1992; 130: 735-40.
30. Smulders RA, Zhang W, Veltkamp SA et al. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes. Metab. 2012; 14: 937-43.
31. Veltkamp SA, van Dijk J, Collins C, van Bruijnsvoort M, Kadokura T, Smulders RA. Combination treatment with ipragliflozin and metformin: A randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clin. Ther. 2012; 34: 1761-71.